Safety of clinical trial participants
HC-BP-210a.1Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials. We operate a system to protect the safety and rights of clinical test participantsWe operate a system to protect the safety and rights of clinical test participants
HC-BP-210a.3Total amount of monetary losses as a result of legal proceedingsViolations of regulations related to clinical trials in developing countries: 0, monetary losses(fines): 0
Access to medicines
HC-BP-240a.2List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP).We obtained WHO PQ Certification for SKY Cellflu Trivalent and Quadrivalent Prefilled
Syringe and Sky Varicella in 2019 Drug safety
HC-BP-250a.3Number of recalls issued, total units recalled.The number of recalls: 0,
Total number of units recalled: 0
HC-BP-250a.4Total amount of product accepted for take-back, reuse, or disposal.The total number of products accepted for take-back, reuse, or disposal: 0
HC-BP-270a.1Total amount of monetary losses as a result of legal proceedings associated with false marketing claims.The number of violations related to domestic marketing activities: 0, total amount of monetary losses(fines): 0.
HC-BP-270a.2Description of code of ethics governing promotion of off-label use of products.We do not conduct any kind of marketing or promotion that may induce off-label prescriptions.
Recruiting, nurturing, and retaining human resources
HC-BP-330a.1Discussion of talent recruitment and retention efforts for scientists and research and development personnel.By defining core competencies for our future business, we expanded target recruitment to attract qualified candidates, and operate HR system for employee growth.
The number of our researchers continues to grow from 121 in 2019, to 146 in 2020, and 208 in 2021.
HC-BP-510a.1Total amount of monetary losses as a result of legal proceedings associated with corruption and briberyFines related to unfair business practices as a result of violation of competition and antitrust laws (including corruption and bribery): 0
HC-BP-510a.2Description of code of ethics governing interactions with health care professionalsWe apply compliance regulations for responsible marketing activities.
We have separate procedures for pre-inspection and post-evaluation of compliance regulations during marketing activities.